The longest documented human life lasted 122 years and 164 days – the record set by Frenchwoman Jeanne Calment in 1997, still unbeaten despite decades of medical progress. The current known as radical life extension assumes that this limit is not a biological ceiling but a technological oversight that can be corrected. It covers very different things: from mTOR inhibitors tested in rigorous studies to cryonics, which is more a bet on the future than a therapy.
Longevity Escape Velocity
Most publications on longevity concern healthspan – preserving fitness for as long as possible within the natural lifespan of the species. Radical life extension aims higher: at the upper limit itself, beyond what we observe today in the oldest people. The biogerontologist Aubrey de Grey called this ambition “longevity escape velocity” – the hypothetical moment at which the pace of progress in anti-aging medicine would exceed the pace at which we age, making death from old age theoretically postponable without end.
The idea itself is not new – the search for an elixir that extends life has accompanied medicine since antiquity. What is new lies in the tools: today we can edit genes, measure a cell’s biological age with a precision unavailable a decade ago, and test interventions on entire animal populations at once. It is this change in the scale of experiment that distinguishes the contemporary movement from earlier, purely speculative searches for immortality – although, as we shall see below, not every branch of this movement makes equal use of those tools.
Freezing for the Future: Cryonics
Cryonics – freezing the body, or the brain alone, immediately after clinical death, in the hope of future revival – occupies a special place in this current, because it is not really an anti-aging intervention but a bet on time. The process relies on vitrification: replacing the water in tissues with a solution of cryoprotectants and cooling to the temperature of liquid nitrogen, so as to minimise the formation of ice crystals that destroy cells.
No mammal subjected to full vitrification and deep freezing has so far been successfully brought back to life. Science has no evidence that the process is reversible, and the cryoprotectant itself is toxic to tissues at high concentrations.
Supporters treat it not as a ready therapy but as a rational bet: the cost of being wrong (losing a body that would have decomposed anyway) seems to them lower than the cost of giving up a chance, however slight. This reasoning is closer to the philosophy of decision-making under uncertainty than to evidence-based medicine – and it is worth reading it that way, without pretending that cryonics today has a status anywhere near that of rapamycin or caloric restriction.
What Animal Research Confirms (and the First Human Trials)
The most convincing data today come from four lines of research:
- Rapamycin – an immunosuppressive drug that inhibits the mTOR pathway, responsible for sensing nutrient availability and regulating cell growth. In genetically diverse mice, administered even late in life, it extended median lifespan by more than ten per cent in both sexes¹.
- Caloric restriction – in rodents it can extend life by as much as several dozen per cent. In humans the effect is markedly more modest: the two-year CALERIE study, in which healthy adults reduced their calorie intake by around 14%, showed a slowing of metabolic rate and improvement in markers associated with aging, but nothing like the leap in lifespan seen in rodents².
- Parabiosis and plasma exchange – experiments joining the circulatory systems of young and old mice showed rejuvenation of the older animal’s tissues; newer work suggests that part of this effect can be obtained by plasma exchange alone, using a saline and albumin solution, without stitching the animals together³.
- Partial cellular reprogramming – the short-term use of Yamanaka factors can turn back a cell’s epigenetic age without converting it back into a stem cell. Preclinical animal studies have observed improved tissue function and the reversal of selected features of aging, partly confirmed by measurements of epigenetic clocks⁴. Recently this approach has also entered clinical trials in humans: the company Life Biosciences is running a phase I trial of a therapy using three of the four classic Yamanaka factors (without the oncogenic MYC, which is intended to limit the risk of tumour formation), administered locally to the eye in patients with optic nerve disease. This landmark moment was discussed for Elevate by Prof. Ewelina Pośpiech.
The difference in scale between these four directions is significant: rapamycin and caloric restriction have decades of replicated research behind them, while cellular reprogramming is only now entering its first human trials. Promising, but still early.
Will We Live to 200? Marek Piotrowski on Lessons from a Journey Around the World in Search of the Secrets of Longevity
Read moreVoices That Temper the Enthusiasm
Not all aging researchers share the optimism around radical life extension. Some scientists argue that advances in understanding the biology of aging do not yet translate into evidence that pharmacological interventions will actually extend the maximum human lifespan, and they warn against confusing promising molecular mechanisms with a ready, proven therapy⁵. That warning sounds familiar in the history of medicine: many promising research paths turned out to be effective in animal models but lost most of their effect on moving to the human organism, far more complex and long-lived than a mouse or a nematode.
Scientific caution need not mean abandoning hope, however. It means rather distinguishing between what is already worth implementing today (sleep, training, control of inflammation, drugs with a well-understood safety profile) and what remains a promising direction of research, requiring years more work before it reaches clinical practice.
Radical Life Extension and the Latest Ways to Turn Back the Biological Clock: Key Insights from Life Summit Berlin
Read moreA Question of Fairness: Who Can Afford It
Beyond biology comes a question harder to settle in a laboratory. The most advanced and expensive anti-aging protocols are today available in practice only to the very wealthy, who have the means to turn their villas into temples of biohacking. This leads some commentators to ask whether radical life extension will become another dimension of inequality, this time measured in years of life rather than merely in income⁶.
There is no single right answer to that question – the history of medicine does, after all, know technologies that began as an expensive privilege and over time became cheaper and widespread, such as vaccines or insulin treatment for diabetes. It is hard to say today on which side of that history radical life extension will fall, but the very possibility that lifespan might become a luxury good certainly deserves attention now, before the technology matures enough for the question to stop being theoretical.
Conclusions
Radical life extension is a field of diverse scientific research in which solid animal results coexist with approaches closer to a philosophical bet than to medicine, such as cryonics. Rapamycin and caloric restriction have well-documented effects, though more modest in humans than in rodents. Scientific scepticism towards radical promises is not a denial of progress, but a reminder that the road from mechanism to therapy is often longer than the headlines suggest.
Sources
1. https://doi.org/10.1038/nature08221
2. https://doi.org/10.1016/j.cmet.2018.04.005
3. https://doi.org/10.18632/aging.103418
4. https://doi.org/10.1038/s41586-020-2975-4
5. https://doi.org/10.1038/s43587-024-00702-3
6. https://holistic.news/en/life-extension-the-rich-want-more-time/
